These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An open-label trial of consensus interferon 15 µg in the treatment of Chinese patients with chronic hepatitis C.
    Author: Hwang S, Lee S, Chu C, Lu R, Chang F.
    Journal: Hepatol Res; 2001 Mar 26; 19(3):284-293. PubMed ID: 11251311.
    Abstract:
    Consensus interferon (CIFN), a novel recombinant type 1 interferon (IFN), has been used recently to treat patients with chronic hepatitis C virus (HCV) infection. CIFN 9 µg, given subcutaneously 3 times a week for 24 weeks, offers sustained biochemical and virological responses in 32% of Chinese patients studied in Taiwan. Whether a higher dosage of CIFN will have greater efficacy is of clinical interest. This open-label trial was conducted to determine the efficacy and safety of CIFN 15 µg, given subcutaneously 3 times a week for 24 weeks, in 35 Chinese patients with chronic hepatitis C who in a previous randomized, controlled CIFN trial received placebo (n=16) or showed no sustained response to CIFN 3 µg (n=14) or 9 µg (n=5), 3 times a week for 24 weeks. Efficacy was assessed by normalization of serum alanine transaminase (ALT) levels and clearance of serum HCV RNA to undetectable levels as measured by reverse-transcription polymerase chain reaction (RT-PCR). Results showed 14 of 35 patients (40%) achieved normalized serum ALT and cleared serum HCV RNA at the end of treatment, and 11 patients (31%) maintained a sustained response 24 weeks after treatment was discontinued. The sustained response rate was 31% in patients who had received a placebo injection in the previous trial, 36% in patients who had relapsed or not responded to previous CIFN 3 µg treatment, and 20% in patients who had relapsed or not responded to previous CIFN 9 µg treatment (P>0.05). Upon re-treatment with CIFN 15 µg, sustained response was achieved in two of three patients who had relapsed from previous CIFN 3 µg treatment and in one of three patients who had relapsed from previous CIFN 9 µg treatment. CIFN 15 µg re-treatment achieved a sustained response in three of eleven patients and in none of two patients who were non-responders from previous CIFN 3 µg or CIFN 9 µg treatments respectively. Patients tolerated the treatment well, but two patients withdrew from the study due to intolerable side effects. In conclusion, subcutaneous injection of CIFN 15 µg, 3 times a week for 24 weeks, showed a similar efficacy as CIFN 9 µg 3 times a week treatment in Chinese patients with chronic hepatitis C. The treatment may benefit patients who have relapsed from a previous 3 µg or 9 µg treatment.
    [Abstract] [Full Text] [Related] [New Search]